Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025 4:01 PM ESTFull year product revenue of $11.02 billion, a 12% increase compared to full year 2023
Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion
ALYFTREK approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX approved in the U.S. for moderate-to-severe acute pain
Diverse late-stage clinical pipeline accelerates with four programs in pivotal development
Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating... More
